Glenmark gets final nod from USFDA for angina treatment drug
The product is a generic version of Gilead Sciences Inc's Ranexa extended-release tablets in the same strengths.
Banks, oil and gas majors may lead 15-20% earnings growth this quarter: Mayuresh Joshi
The markets might remain very volatile in shor term, s...
Sell Lupin, target Rs 800: Elara Capital
Sell Lupin at a price target of Rs 800.
Lupin launches chronic angina treatment drug in the US
The newly launched product, in strengths of 500 mg and 1,000 mg, is a generic version of Gilead Sciences' Ranexa ER tablets, Lupin said.
Buy Lupin, target Rs 985: HDFC Securities
Buy Lupin at a price target of Rs 985.
Buy Lupin, target Rs 1,030: HDFC Securities
Buy Lupin at a price target of Rs 1030.
For every rupee depreciation, we expect to add Rs 40 cr to bottom line: Ramesh Swaminathan, Lupin
“Between 25% and 30% of our total exposures are hedged.”
Buy Lupin, target Rs 1190: HDFC Securities
Buy Lupin Ltd. at a price target of Rs 1190.
Good home show to help Lupin limit fallout of US woes
Indian pharmaceutical cos are facing regulatory issues and steep competition in US market.
Lupin still on track to meet $800-million FY19 sales target: Ramesh Swaminathan
Things not as bad as they were in the past and should be looking better, says Lupin CFO.
Lupin gets USFDA nod for heart disease drug
According to IMS Health data, the tablets posted sales of around $ 443.4 million in the US for the twelve months ending March, 2013.
Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service